Health Condition 1: H539- Unspecified visual disturbance
Conditions
Interventions
Intervention1: Nanodropper-mediated microdrops of proparacaine HCL 0.5%: Each study participant will receive on single drop of proparacaine hydrochloride0.5% following which Conjunctival pinch tests
Sponsors
Nanodropper, Inc.
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients >= 18 years 2) Ability to provide informed consent for mode of topical anesthesia delivery 3) Ability to verbally respond to pain 4) Receiving treatment at AEH OPD (patient has undergone a preliminary examination and is awaiting dilation)
Exclusion criteria
Exclusion criteria: 1)Have a contraindication to local anaesthetics. 2)Intravitreal injection within the past 14 days. 3)Recent ocular surgery within the past 4 weeks. 4)Preexisting diagnosis of ocular surface disease. requiring punctal plug placement. 5)Evidence of any current ocular inflammation/infection. 6)Any previous ocular condition (i.e., neurotrophic keratitis, herpetic eye disease, presence of a corneal graft, etc.) that has permanently altered the native sensation of the ocular surface. 7) Use of contact lenses. 8) Use of exclusionary medications: 9) Topical steroid drops, NSAIDS, IOP lowering eye drops, any anti-viral medications used for herpes, Opioids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The results of this study might implicate the nanodropper as a viable and desirable solution to oversized drop-induced waste.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| It may further support the revision of existing institutional policies to allow for extended use of multi-dose bottles Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Indira Durai
Aravind Eye Hospital and Postgraduate Institute of Ophthalmology
Outcome results
None listed